Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Effect Relationship of a Single Dose of Rituximab on B-Lymphocyte Kinetics in Acute ST-Segment Myocardial Infarction
2016-000211-33Phase 2Completed
- Sponsor
- Papworth Hospital NHS Foundation Trust
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of rituximab in myocardial infarction (MI), sponsored by Papworth Hospital NHS Foundation Trust. Primary endpoint: Safety of rituximab in STEMI patients. Started Aug 2016; status: completed.
02
Drugs
rituximab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2016-000211-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000211-33.